BenevolentAI’s Post

Celebrating Rare Disease Research on the Rarest Day of the Year - Moderna's Rare Disease portfolio includes therapies targeting methylmalonic acidemia (MMA), propionic acidemia (PA), glycogen storage disease (GSD1A) and Phenylketonuria (PKU). We're targeting up to 4 product launches in the next 5 years!!! Check out the article below and if you are a Pediatrics MD or an experienced Clinical Scientist in the industry, let's connect to discuss the possibilities of Moderna! #nowhiring #rarediseaseday #clinicaldevelopment

"Infliximab is an anti-inflammatory medicine for the treatment of rheumatoid arthritis (RA), Crohn’s disease, paediatric CD, ulcerative colitis (UC), paediatric UC, radiographic axial spondyloarthritis (ankylosing spondylitis), psoriatic arthritis (PsA) and psoriasis. Golimumab is also an anti-inflammatory medicine that treats RA, polyarticular juvenile idiopathic arthritis, PsA, radiographic axial spondyloarthritis (ankylosing spondylitis), non-radiographic axial spondyloarthritis and UC." Johnson & Johnson #Medicine #DrugDiscovery #Immunology #InfectiousDiseases #Oncology #Development #Research https://lnkd.in/eqKrZFiT

Our inaugural issue of The Quill Quartet is here! Four things you might have missed in immunology/rheumatology from the past couple of months. Read more: ▪️Circulating regulatory T cells: https://buff.ly/4f9Qc1i ▪️Digital health in rheumatoid arthritis (RA): https://buff.ly/3W8tgXq ▪️Tyenne approved by the FDA: https://buff.ly/3Wr3Kht ▪️ Long-term safety and efficacy of CAR-T cell treatment in severe and treatment refractory autoimmune disease: https://buff.ly/4fb2LZY More about the CAR-T study: In data presented at EULAR 2024, patients with refractory lupus (SLE n=8), systemic sclerosis (SSc, n=4), and idiopathic inflammatory myositis (IIM=3) were treated with experimental CD19-targeting CAR T cell therapy. At ≥1 year after treatment (median follow-up of 18 months), all 15 patients had stopped immunosuppressive therapy. All patients achieved remission as defined by DORIS remission (SLE), all IIM patients reached ACR/EULAR major response (IIM) and improvement in the EUSTAR activity index (SSc).

Enjoyed this new article “Understanding Checkpoints: New Hope For Autoimmunity” that draws warranted attention to checkpoint agonists and their potential to drive meaningful change for autoimmune diseases. This year has been an exciting one for Immutep Limited in regard to our checkpoint agonist program targeting the LAG-3 checkpoint. Our novel LAG-3 antibody agonist called IMP761 entered the clinical stage this summer, and recently advanced to the dose escalation portion of our first-in-human Phase I trial. LAG-3 has been identified as a promising target to potentially treat many autoimmune diseases, including rheumatoid arthritis and Type 1 diabetes, and we look forward to sharing additional updates on IMP761 as the Phase I trial progresses. #LAG3

What’s the future of bispecific antibodies (BsAbs) in relapsed #MultipleMyeloma? A recent review in Frontiers in Immunology dives into the game-changing role of BsAbs, showing high response rates in heavily pre-treated patients. But what about the best patient population, treatment sequence, and long-term use? Ongoing studies aim to answer these crucial questions. This paper also explores: 🔬 Lower CRS/neurotoxicity vs CAR-T ⚠️ High infection risks 💭 Resistance from chronic BsAb therapy 🧬 Novel T-cell engagers in development Open access article by Rees et al. here: https://ow.ly/XYQW50TKwja #MM #MedEd #MMSM

Looking forward meeting you in the poster session A71 at ATS San Diego today. ‼️CUTTING EDGE TECHNOLOGIES FOR LUNG DISCOVERY 🫁 Poster: 📌„Effective Pharmacological Modulation of Biomarkers in Lung Tissue of Pulmonary Fibrosis Patients Ex Vivo“ Don’t miss the other poster contributions of my colleagues: 📅 On Sunday, May 19: ▶ Chip cytometry for simultaneous measurement of protein and mRNA markers on single cell level ▶ Ex Vivo Testing of Antifibrotic Drugs in a Long-term Culture of Precision-cut Lung Slices (PCLS) ▶ Ex-vivo Evaluation of the Potential for Narrow Spectrum Kinase Inhibitors as a Treatment for Idiopathic Pulmonary Fibrosis ▶ CXCL10+ Monocyte-derived Macrophages Are Potential Drivers of TH17.1 Inflammation in Pulmonary Sarcoidosis 📅 On Monday, May 20: ▶ Comprehensive analysis of bronchoalveolar lavage fluid by validating ELISA and MSD systems for 23 biomarkers ▶ Integrated In Vitro/Ex Vivo Assessment of Efficacy and Respiratory Toxicity for Accelerated Respiratory Drug Development ▶ Combined Rhinovirus Infection and Cigarette Smoke Exposure of Normal Human Epithelial Cells and Distal Lung Tissue Ex Vivo Induces Dysregulation of Human Airway Basal Cells 📅 On Tuesday, May 21: ▶ Transcriptomic characterization of type 2 innate lymphoid cells from asthma patients in response to prostaglandin D2 metabolites ▶ Inhaled LNP-formulated siRNA Inhibits Human Parainfluenza Virus Type 3 Infection: From Bench to Bedside ▶ Role of Tumor Necrosis Factor Superfamily Member 10 (TNFSF10) in SARS-CoV2-infection-associated Lung Damage

🎖️ Check out the Editor's Choice Review "MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges" 👏 by Anju G. S. Phoolchund and Salim I. Khakoo, University of Southampton 📌 Link here: [MASLD and the Development of HCC](https://t.ly/x_h-o) 🔸 Metabolic-dysfunction-associated steatotic liver disease (MASLD), a newly established disease concept in 2020, is rapidly associated with chronic liver disease, sometimes followed by the onset of primary liver cancer. This review focuses on hepatocellular carcinoma in MASLD and insists on the need to establish new scoring systems to identify high-risk patients for the initiation of HCC surveillance. 🔸 --- **Interactive Questions:** 1. **What is MASLD, and why is it significant in the context of liver disease?** - **Answer:** MASLD stands for Metabolic-dysfunction-associated steatotic liver disease, a condition that was recognized in 2020. It is significant because it is rapidly associated with chronic liver disease and can lead to the development of primary liver cancer (HCC). 2. **Why is there a need for new scoring systems for MASLD patients?** - **Answer:** There is a need for new scoring systems to identify high-risk MASLD patients who require surveillance for hepatocellular carcinoma (HCC). Early identification can lead to timely interventions and better outcomes. 3. **How does MASLD contribute to the development of hepatocellular carcinoma (HCC)?** - **Answer:** MASLD can lead to chronic liver inflammation and fibrosis, creating an environment that fosters the development of hepatocellular carcinoma (HCC). --- Join the discussion and share your thoughts! How can we improve the early detection and management of HCC in patients with MASLD? #MASLD #LiverDisease #HCC #HealthcareInnovation

We have just celebrated an International Day of Immunology under the theme: Immunity Through the Ages: Navigating the Science of Aging and Immunology. Here at Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO)- University of Geneva multiple groups work on various topics from vaccines to understanding diseases and fight against infection, autoimmunity, and cancer. #ImmunologyDay #ImmunityThroughTheAges #CelebrateImmuneSystem

Chronic Rhinosinusitis with Primary Antibody Deficiency: An Underrecognized Condition Primary antibody deficiency (PAD) can occur in up to 50% of patients with recalcitrant chronic rhinosinusitis (CRS), making a multidisciplinary collaboration with clinical immunology crucial to optimal management of the condition. https://ow.ly/C7zM50RyAiQ

🔈 Research by Lida Iliopoulou in George KOLLIAS #lab delineates IL-12 and IL-23 implications in #Crohn’s Disease. The recent study, published in Mucosal Immunology, identified interleukin 23 (IL-23) as a dominant #cytokine driving the progression of #Crohn’s disease (CD), a severe form of inflammatory bowel disease (IBD) affecting the #ileum. While Ustekinumab, a widely used monoclonal antibody, targets both interleukin 12 (IL-12) and IL-23, which of the two cytokines is mainly involved in CD progression, remained poorly understood. The research study revealed that IL-23 plays a far more critical role in perpetuating inflammation, with IL-12 only contributing when IL-23 is absent. Read more 👉 https://lnkd.in/gXmXws4Q